Acute renal failure due to sulphadiazine crystalluria in AIDS patients

P de Sequera, M Albalate, J Hernandez, A Vazquez, J Abad, E Ramiro, M Fernández Guerrero, C Caramelo, S Casado, A Ortiz

Summary
We report two AIDS patients who developed acute renal failure while receiving sulphadiazine for cerebral toxoplasmosis. Renal ultrasound revealed diffuse bilateral echogenic shadowing material. 'Sheaves of wheat' crystals, typical of sulphadiazine crystalluria, were present in the urine. One patient required a percutaneous nephrostomy. Hydration and urine alkalinisation resulted in rapid improvement of renal function and ultrasonographic findings. Sulphadiazine-induced crystalluria and acute renal failure is increasingly frequent. Awareness of its existence may lead to prevention and early conservative treatment.

Keywords: sulphadiazine, crystalluria, renal failure, AIDS

Sulphonamides are among the drugs that may precipitate in acid urine and give rise to crystalluria and calculi. In recent years, sulphadiazine, in association with pyrimethamine, has become standard therapy for cerebral toxoplasmosis, a frequent complication of the acquired immune deficiency syndrome (AIDS) and other immunodeficiency states.

The progression of the AIDS epidemic has been accompanied by an increased use of sulphadiazine, and a re-emergence of its adverse effects. Renal failure is one of these 'forgotten' complications.

Case 1
An HIV-positive 31-year-old man presented with vomiting, left flank pain that radiated to the groin, oligoanuria and dark urine. An evaluation one month before admission for fever and right hemiparesis disclosed an intracerebral mass suggestive of cerebral toxoplasmosis. Sulphadiazine (1 g/6 h), pyrimethamine (25 mg/day), and folinic acid were begun seven days before admission. At that time renal function was normal (serum creatinine 88 μmol/l).

On admission, his body temperature was 36°C and blood pressure 120/80 mmHg. Significant initial laboratory values were: creatinine 858 μmol/l, urea 22 μmol/l. Urinalysis revealed gross haematuria, and many crystals with a characteristic 'sheaves of wheat' morphology (figure 1). A plain abdominal X-ray showed normal-sized kidneys with no evidence of calculi. Renal ultrasound demonstrated bilateral multiple diagnostic echogenic foci with shadowing consistent with calculi. There was no hydronephrosis. Diuresis for the first 24 hours was 200 ml.

Sulphadiazine was discontinued and he was intravenously hydrated with 1/6 M NaHCO₃ and 0.9% sodium chloride. After 24 h he was challenged with 250 mg furosemide intravenously, and diuresis over the next 24 hours was 6 l. Urine pH was 7.5. Renal function improved rapidly over the next several days. On day 8, urea was 3.8 μmol/l; creatinine 92 μmol/l, and a repeat ultrasound revealed absence of calculi.

Figure 1 Characteristic 'sheaves of wheat' crystals and numerous red blood cells in urine
first 12 hours. A left nephrostomy catheter was inserted and minimal diuresis was obtained. Brisk diuresis was only observed after an intravenous furosemide 250 mg challenge. Thereafter, renal function and urinary output improved rapidly. On day 6, creatinine was 132 μmol/l, and a repeat ultrasound revealed absence of calculi.

Discussion

Obstructive renal failure associated with sulphadiazine has been recognised since the 1940s. However, with the advent of newer, safer antibiotics, this complication all but disappeared from the medical literature, only to re-emerge in the wake of the AIDS epidemic. Sulphonamides precipitate in the urinary tract due to their low solubility in acid media, especially in the presence of dehydration and hypalbuminaemia, two conditions that are common in AIDS patients. Sulphadiazine has a relatively low urine solubility, so that for the usual daily dose of 4 g, approximately 16 l of urine at a pH of 5.5 need to be produced to keep the drug in solution. The amount of sulphadiazine excreted without crystallisation can be increased more than 10-fold by increasing urinary pH from 5.5 to 7.5.

Renal toxicity usually develops after three days of sulphadiazine therapy, although it has been reported following a single large dose. Sulphadiazine crystalluria should be suspected when acute renal failure develops in patients receiving sulphadiazine, especially if there are symptoms of renal colic. Confirmation of the diagnosis requires demonstration of radiolucent urinary lithiasis by ultrasound and plain abdominal X-ray, as well as urinalysis that reveals the characteristic 'sheaves of wheat' crystals. A high degree of clinical suspicion and early diagnosis may lead to prompt conservative treatment with alkaline hydration and may prevent the need for renal biopsy, dialysis or invasive urologic manipulation, all of which have been employed in reported cases of sulphadiazine crystalluria. Alkaline diuresis should always be induced, as intratubular sulphadiazine deposition will not be relieved by urinary catheterisation. However, in severe cases, urinary catheterisation and/or lavage with 5% sodium bicarbonate may be required.

In conclusion, clinicians caring for AIDS patients should be aware of the potential of sulphadiazine to cause acute renal failure. Prophylactic adequate hydration and urine alkalinisation should be ensured in patients receiving sulphadiazine.

---

Acute renal failure due to sulphadiazine crystalluria in AIDS patients.


doi: 10.1136/pgmj.72.851.557

Updated information and services can be found at:
http://pmj.bmj.com/content/72/851/557

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/